Mumbai, July 08, 2025: Godavari Biorefineries Limited (GBL) announced that its European patent for a novel anti-cancer molecule has now been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple European Union member states. The development marks a significant milestone in the company’s efforts to expand its global footprint in scientific innovation through its dedicated Anti-Cancer Research Segment.
The patented molecule has demonstrated promising results in targeting both cancer cells and cancer stem cells, offering potential advances in therapies for breast and prostate cancer. Preclinical studies in animal models have indicated encouraging efficacy and safety outcomes. The molecule is currently undergoing Phase 1a clinical trials involving patients with advanced solid tumors as well as healthy volunteers to evaluate safety and tolerability.
“This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research. It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation,” said Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited.
The development is driven by GBL’s clinical-stage biotech division, Sathgen Therapeutics, which focuses on advancing novel treatments for cancer and viral infections. The validation of the patent strengthens GBL’s strategic positioning in the field of translational medical research.
Godavari Biorefineries exports to over 20 countries and maintains close collaborations with global R&D networks. The company’s diversification into biotech innovation complements its existing leadership in the ethanol, bio-based chemicals, and renewable materials sector.
GBL continues to expand its innovation pipeline while maintaining a focus on sustainable development and circular economy principles.
x
.jpg)
